Capturing the value of traditional in vitro diagnostic tests
This article was originally published in Clinica
Given the attention currently focused on advanced diagnostics – such as genetic, gene-expression and algorithm-based testing and companion diagnostics – it is easy to forget that the vast majority of diagnostic testing still comprises more traditional clinical lab tests. These haematology, chemistry, immunochemistry, microbiology and other "simple" tests account for most of the spending in a global market estimated by Boston Healthcare at $25-35bn annually. Yet in an increasingly cost-pressured healthcare market, traditional in vitro diagnostic (IVD) testing is a ripe target for cost-containment measures. The aggregated global market consists of hundreds of millions of relatively low-cost tests, each of which may seem to contribute little to clinical care individually. It is therefore a challenge for IVD manufacturers to maximise the value of these tests in the face of this pressure.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.